

Cambium Bio Limited

ABN 13 127 035 358

ASX Announcement

8 April 2024

Change of Company Name and ASX Code

The Board of Regeneus Ltd (**Regeneus** or **Company**) is pleased to have received shareholder approval at the General Meeting held on 28 March 2024 to change the Company name from Regeneus Ltd to **Cambium Bio Limited**. The Company's name change has now been completed at the Australian Securities and Investments Commission.

The effective date for the change of Company Name on the ASX will be **10 April 2024** and the new ASX Listing Code will be **CMB** (formerly RGS).

- ENDS -

About Cambium Bio Limited (formerly named Regeneus Ltd)

Cambium Bio Limited (formerly named Regeneus Ltd) (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio or www.regeneus.com.au.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited